Reduction of portosystemic gradient during transjugular intrahepatic portosystemic shunt achieves good outcome and reduces complications

Shi-Hua Luo,Mi-Mi Zhou,Ming-Jin Cai,Shao-Lei Han,Xue-Qiang Zhang,Jian-Guo Chu
DOI: https://doi.org/10.3748/wjg.v29.i15.2336
IF: 5.374
2023-04-21
World Journal of Gastroenterology
Abstract:BACKGROUND: Transjugular intrahepatic portosystemic shunt (TIPS) is placed important role in the therapy of complications of portal hypertension, there is still no suitable criterion for a reduction in portosystemic gradient (PSG), which can both reduce PSG and maximize clinical results and minimize hepatic encephalopathy (HE).AIM: To compare the clinical outcomes and incidence of HE after one-third PSG reduction during TIPS in patients with variceal bleeding and refractory ascites.METHODS: A total of 1280 patients with portal-hypertension-related complications of refractory ascites or variceal bleeding who underwent TIPS from January 2016 to January 2019 were analyzed retrospectively. Patients were divided into group A (variceal hemorrhage and PSG reduced by one third, <i>n</i> = 479); group B (variceal hemorrhage and PSG reduced to &lt; 12 mmHg, <i>n</i> = 412); group C (refractory ascites and PSG reduced by one third, <i>n</i> = 217); and group D (refractory ascites and PSG reduced to &lt; 12 mmHg of PSG, plus medication, <i>n</i> = 172). The clinical outcomes were analyzed.RESULTS: By the endpoint of follow-up, recurrent bleeding was no different between groups A and B (<i>χ</i> <sup>2</sup> = 7.062, <i>P</i> = 0.374), but recurrent ascites did differ significantly between groups C and D (<i>χ</i> <sup>2</sup> = 14.493, <i>P</i> = 0.006). The probability of total hepatic impairment within 3 years was significantly different between groups A and B (<i>χ</i> <sup>2</sup> = 11.352, <i>P</i> = 0.005) and groups C and D (<i>χ</i> <sup>2</sup> = 13.758, <i>P</i> = 0.002). The total incidence of HE differed significantly between groups A and B (<i>χ</i> <sup>2</sup> = 7.932, <i>P</i> = 0.016), groups C and D (<i>χ</i> <sup>2</sup> = 13.637, <i>P</i> = 0.007). There were no differences of survival rate between groups A and B (<i>χ</i> <sup>2</sup> = 3.376, <i>P</i> = 0.369, log-rank test), but did differ significantly between groups C and D (<i>χ</i> <sup>2</sup> = 13.582, <i>P</i> = 0.014, log-rank test).CONCLUSION: The PSG reduction by one third may reduce the risk of HE, hepatic function damage and achieve good clinical results.
gastroenterology & hepatology
What problem does this paper attempt to address?